A Systematic Review of Cost-effectiveness Analyses of
Durvalumab Consolidation Therapy Versus no Consolidation
Therapy After Chemoradiotherapy in Stage-III NSCLC

a 2022

A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR

Základní údaje

Originální název

A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC

Autoři

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR

Vydání

GIN 2022, Toronto, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Durvalumab; Cost-effectivness analysis; NSCLC

Změněno: 10. 10. 2022 14:43, Mgr. Bc. Alena Langaufová, Ph.D.

Anotace

V originále

Background Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. To date, economic studies from different parts of the world presented varying findings. Objective So, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane Central databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of CHEERS 2022 checklists. Incremental cost-effectiveness ratio (ICER) data were converted to 2022 US dollars ($). Results A total of seven studies were found to be eligible for inclusion. The healthcare payers’ perspective was the most common study perspective among the included studies. Four included studies used the Markov model. The ICER of durvalumab consolidation therapy after unresectable stage III NSCLC in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries was found to be in the range of $62,021 to $76,068 per QALY. Durvalumab was found to be cost-effective among all the included studies as the ICER was below the implemented country-specific willingness-to-pay thresholds. Conclusion Durvalumab consolidation therapy was found to be cost-effective versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.

Citovat

HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ a Miloslav KLUGAR. A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC. In GIN 2022, Toronto. 2022.

@proceedings{2223877,
   author = {Hussain, Mohammad Salman and Klugarová, Jitka and Klugar, Miloslav},
   booktitle = {GIN 2022, Toronto},
   keywords = {Durvalumab; Cost-effectivness analysis; NSCLC},
   language = {eng},
   title = {A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC},
   url = {http://icsevents.eventsair.com/gin2022/},
   year = {2022}
}

TY  - CONF
ID  - 2223877
AU  - Hussain, Mohammad Salman - Klugarová, Jitka - Klugar, Miloslav
PY  - 2022
TI  - A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC
KW  - Durvalumab
KW  - Cost-effectivness analysis
KW  - NSCLC
UR  - http://icsevents.eventsair.com/gin2022/
N2  - Background Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. To date, economic studies from different parts of the world presented varying findings. Objective So, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane Central databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of CHEERS 2022 checklists. Incremental cost-effectiveness ratio (ICER) data were converted to 2022 US dollars ($). Results A total of seven studies were found to be eligible for inclusion. The healthcare payers’ perspective was the most common study perspective among the included studies. Four included studies used the Markov model. The ICER of durvalumab consolidation therapy after unresectable stage III NSCLC in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries was found to be in the range of $62,021 to $76,068 per QALY. Durvalumab was found to be cost-effective among all the included studies as the ICER was below the implemented country-specific willingness-to-pay thresholds. Conclusion Durvalumab consolidation therapy was found to be cost-effective versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.
ER  -

Podrobný výpis o publikaci